Search results
Sanofi forecasts moderate profit growth on Dupixent demand
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
Sanofi's Dupixent wins U.S. approval for bigger use
Reuters via Yahoo News· 2 years agoThere are more than 160,000 patients in the United States living with eosinophilic esophagitis (EoE), according to Sanofi. Sanofi's regulatory filing for...
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi's asthma drug Dupixent met all targets in a trial to treat "smoker's lung",...
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
Zacks via Yahoo Finance· 1 year agoRegeneron Pharmaceuticals, Inc. REGN is having a good run, with shares gaining 16.4% in the year so...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 1 month agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
Sanofi lifts earnings outlook on new drug launches, Dupixent sales
Reuters via Yahoo Finance· 9 months ago(Reuters) -French drugmaker Sanofi on Friday increased its guidance for full-year earnings, citing...
Could Regeneron Stock Help You Retire a Millionaire?
Motley Fool via Yahoo Finance· 3 months agoThere are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among...
Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers
Investor's Business Daily· 6 months agoRegeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
Zacks via Yahoo Finance· 2 years agoThe biotech sector has been in the spotlight in the past week, with regular pipeline and regulatory...
Sanofi (SNY) Q1 2023 Earnings Call Transcript
Motley Fool· 12 months agoImage source: The Motley Fool. Sanofi (NASDAQ: SNY) Q1 2023 Earnings Call Apr 27, 2023, 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers...
